Global Parathyroid Disease Treatment Market, By Treatment (Calcimimetics, Bisphosphonates, Plicamycin, Hormone Replacement Therapy, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Parathyroid Disease Treatment Market Analysis and Size
The global parathyroid disease treatment market is expected to witness significant growth during the forecast period. A study published in BMC Endocrine Disorder specified that parathyroid cancer is a rare type of endocrine malignancy mainly diagnosed in patients with primary hyperparathyroidism. Hypoparathyroidism affects around 200, 000 people, out which maximum cases are associated with accidental damage or removal of the parathyroid gland during thyroid surgery. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global parathyroid disease treatment market in the forecast period 2022-2029. The expected CAGR of global parathyroid disease treatment market is tend to be around 6.50% in the mentioned forecast period. The market was valued at USD 2 billion in 2021, and it would grow upto USD 3.31 billion by 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Parathyroid disease is subtype of endocrine disorders that might be defined as the abnormal level of calcium in blood that results in a disturbance in the balance and might causes fatigue, brittle bones, kidney stones, chronic pain, weakness and many other complications. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Parathyroid Disease Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Calcimimetics, Bisphosphonates, Plicamycin, Hormone Replacement Therapy, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Teva Pharmaceutical Industries Ltd (Israel), Mylan N.V (U.S.), Johnsons & Johnsons Services Inc (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), Lilly (U.S.), Merck & Co., Inc. (U.S.), Aurobindo Pharma (India), , Bristol-Myers Squibb Company (U.S.), GSK plc (U.K.), Ascendis Pharma A/S (Denmark)
|
|
Market Opportunities
|
|
Global Parathyroid Disease Treatment Market Dynamics
Drivers
- Increased Incidence of Parathyroid Disorders
Thyroid Disorders, mainly hyperthyroidism, affect 200 million people globally; in most countries, half of the population remains undiagnosed. This condition is more predominant among women and the elderly. Increase in occurrence of parathyroid diseases is anticipated to boost the growth of the global parathyroid disease treatment market. Recently, a study stated that between 2003 and 2017, it is estimated that 13,897 admissions corresponding to 12,903 patients registered with parathyroid gland disorder were stated in Spain. As per the reports of Informa U.K. Limited, primary hyperparathyroidism (pHPT) is the third most common endocrine disorder. This boosts the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increase in Elderly Population
Increase in elderly population is anticipated to boost the market size. Parathyroid problems are more common in younger adults between the age group of 30 to 40 years and older people. Therefore, rise in the elderly population is likely create opportunities the growth of the global market. As per the article published in journal of the Endocrine Society, a retrospective survey was conducted from January 1997 to June 2018, which projected that 462 patients were diagnosed with primary hyperparathyroidism and 212 were aged above 65.
- Increased Research Activities
Focus on research & development by major market players is expected to drive the global parathyroid disease treatment market. For instance, in June 2017, Amgen, Inc. received positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Marketing Authorization of a pediatric formulation, Mimpara (cinacalcet), for children aged three years and above having secondary hyperparathyroidism (HPT). Thus, these policies drive the market growth.
- Increasing Adoption of Biosimilars
Many major market players in parathyroid hormones market are concentrating on developing a biosimilar of parathyroid based drugs. Biosimilars mainly offer consumers the opportunity to decrease their health care costs treatment standards same, thus parathyroid hormones manufacturing companies are investing hugely in it. For instance, in August 2019, Gedeon Richter announced the launch of biosimilar teriparatide caledTerrosa in Europe. In August 2020, Cadila Pharmaceuticals launched a teriparatide biosimilar (NuPTH) for osteoporosis.
Restraints/Challenges
- Product Recall by FDA
The product recall by the Food and Drug Administration (FDA) likely hinders the growth of the global parathyroid disease treatment market. For instance, in September 2019, the Takeda Pharmaceutical Company Limited issued the U.S. recall of NATPARA. The recall is because of a potential issue associated with rubber particulates rising from the rubber septum of the NATPARA cartridge.
- Limiting Adoption of Hormonal Therapy
In most cases, oral medications are considered standard treatment for hypoparathyroidism. This restricts the adoption of available hormonal therapy. Additionally, long-term beneficial drug usage symptoms have still not been revealed across clinical trials, which might limit the adoption of therapy in patients. According to the Drug literature review 2018, therapy with rhPTH (1-84) is a long-term management option, where more long-term efficacy and safety data are needed in humans. Thus, it restricts the growth of the market.
This global parathyroid disease treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global parathyroid disease treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Parathyroid Disease Treatment Market
The COVID-19 has impacted the healthcare sector harshly. While, clinical trials for the rare diseases are postponed through 2020 as priority was given to the development of lifesaving drugs, the market for hypoparathyroidism is expected to witness a short-term fall even during 2021.
But, in the post-pandemic era, the market is expected to flourish. Governmental support in the form of funding and grants to support the expansion of new hormonal therapy, the relaxation of lockdown regulations is projected to provide several opportunities for market growth. As a result, the market is anticipated to grow at a steady pace during the forecast period.
Recent Development:
- In March 2021, BridgeBio Pharma declared the positive outcomes from its 2nd stage trial of its new drug encaleret. Considering the hypoparathyroidism treatments, the drug has shown immense effectiveness among patients having autosomal dominant hypocalcemia type 1.
Global Parathyroid Disease Treatment Market Scope
The global parathyroid disease treatment market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Calcimimetics
- Bisphosphonates
- Plicamycin
- Hormone Replacement Therapy
- Others
Route of Administration
- Oral
- Parenteral
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Parathyroid Disease Treatment Market Regional Analysis/Insights
The global parathyroid disease treatment market is analysed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global parathyroid disease treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the countries' high prevalence of parathyroid diseases and advanced healthcare facilities.
Asia-Pacific dominates the market due to the increasing cases of cardiovascular diseases and rapidly aging population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Parathyroid Disease Treatment Market Share Analysis
The global parathyroid disease treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global parathyroid disease treatment market.
Key players operating in the global parathyroid disease treatment market include:
- Teva Pharmaceutical Industries Ltd (Israel)
- Mylan N.V (U.S.)
- Johnsons & Johnsons Services Inc (U.S.)
- F. Hoffman-La Roche Ltd. (Switzerland)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- Aurobindo Pharma (India)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc (U.K.)
- Ascendis Pharma A/S (Denmark)
SKU-